As might be expected, the Biotechnology Industry Organization (BIO), which represents such companies as Novo Nordisk, Eli Lilly and Company and Sanofi Aventis immediately disputed the Express Scripts estimates, adding that they doubted the validity of both the Express Scripts study and the PCMA study.